Home 
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.7, p.443–448,2021
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.7, p.443–448,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.7, p.443–448,2021 |
||
| Title: Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data | ||
| Author: M. Lassanova, S. Liskova, J. Tisonova, S. Fundarkova, S. Lassan | ||
| Abstract: OBJECTIVES: Biopharmaceuticals improved the prognosis and quality of life of patients with chronic diseases. The aim of our study was to analyse the total reported suspected adverse drug reactions (ADR) and ADRs of reference biologicals and their biosimilars in Slovakia. METHODS: Using data from the State Institute for Drug Control database, we analysed the trends of suspected ADR submitted between 2001–2017 including the registered biosimilars and their reference biologicals: erythropoietin, filgrastim and infliximab. RESULTS: Severe suspected ADR represented 42.95 % from all the reported cases (n=13,462) over the time period 2006–2017 and 54.98 % over 2015–2017 respectively. Reports from 2015–2017 were further analysed. From 4,364 cases, 27 were associated with infliximab and one with erythropoietin. 75 % of these ADR were severe including one death. The difference between the suspected ADR for infliximab reference biological compared to the biosimilar was not statistically significant (p=0.171) after adjustment to the number of prescribed drug units. CONCLUSION: We did not find any evidence of increased risks associated with biosimilars compared to reference biologics. The spontaneous reporting system represents an inexpensive tool of reporting ADRs and should be utilized more frequently by health professionals, but even more importantly, by patients (Tab. 3, Fig. 2, Ref. 30). Text in PDF www.elis.sk |
||
| Keywords: adverse drug reaction, spontaneous reporting, biopharmaceuticals, biosimilars, infliximab | ||
| Published online: 23-Jun-2021 | ||
| Year: 2021, Volume: 122, Issue: 7 | Page From: 443, Page To: 448 | |
| doi:10.4149/BLL_2021_073 |
||
|
|
 download file |
|